GDC-0077 Chemical Properties

Boiling point:

698.0±65.0 °C(Predicted)

Density 

1.63±0.1 g/cm3(Predicted)

storage temp. 

Store at -20°C

solubility 

DMSO:110.0(Max Conc. mg/mL);245.47(Max Conc. mM)

pka

15.89±0.50(Predicted)

form 

Solid

color 

Off-white to yellow

InChIKey

SGEUNORSOZVTOL-CABZTGNLSA-N

SMILES

C(N)(=O)[C@@H](NC1C=C2OCCN3C=C(N4[C@H](C(F)F)COC4=O)N=C3C2=CC=1)C

GDC-0077 Usage And Synthesis

Description

Inavolisib, or GDC-0077, is a potent and selective PI3K inhibitor. GDC-0077 blocks an enzyme involved in cancer growth called PI3K. GDC0077 binds to and inhibits various members of the PI3K family, including activating mutations in the catalytic alpha isoform PIK3CA. PI3K inhibition prevents the activation of the PI3K-mediated signaling pathway and inhibits the growth and survival of PI3K-overexpressing tumor cells. The IUPAC name of this compound is (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide.

Uses

Inavolisib (GDC-0077) is a potent, orally active, and selective PI3Kα inhibitor (IC50=0.038 nM). Inavolisib exerts its activity by binding to the ATP binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3. Inavolisib is more selective for mutant versus wild-type PI3Kα. Inavolisib can be used for the study of breast cancer[1].

in vitro

GDC-0077 (RG6114) is >300-fold more selective for PI3Kα over the other class I PI3K isoforms (β, δ, and γ) and >2000-fold more selective over PIK family members. GDC-0077 selectively degrades mutant PI3Kα in a proteasome-dependent fashion, resulting in a reduction of PI3K pathway activity biomarkers such as pAKT and pPRAS40, inhibition of cell proliferation, and increased apoptosis in human PIK3CA-mutant breast cancer cell lines to a greater extent when compared to PIK3CA wild-type cells.

in vivo

IC 50

PI3Kα: 0.038 nM (IC₅₀)

References

[1] R Hong, Abstract PD4-14: GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies. 2017 San Antonio Breast Cancer Symposium.

GDC-0077(2060571-02-8)Related Product Information

• 2-Propen-1-one, 1-[(3S)-4-[(7R)-7-[6-amino-4-methyl-3-(trifluoromethyl)-2-pyridinyl]-6-chloro-8-fluoro-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]-4-quinazolinyl]-3-methyl-1-piperazinyl]-
• GDC-0623
• GDC0575
• (R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopropanecarboxamide
• 2,6-dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
• (S)-1-[4-[[2-(2-Aminopyrimidin-5-yl)-7-methyl-4-(morpholin-4-yl)thieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one
• XL518
• DONEPEZIL HYDROCHLORIDE
• TDZD-8
• 4SC-202
• CEP-32496
• N2-[2-Methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-1,3,5-triazine-2,4-diamine
• PURVALANOL A
• Testolactone
• AGI6780
• CC0651
• 6-Amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-9H-purine-9-propanamine
• IDO-IN-7